Azmi Nabulsi M.D., M.P.H.
Net Worth

Last updated:

What is Azmi Nabulsi M.D., M.P.H. net worth?

The estimated net worth of Dr. Azmi Nabulsi M.D., M.P.H. is at least $11,031,339 as of 15 Jul 2024. He owns shares worth $2,536,442 as insider, has earned $4,855,047 from insider trading and has received compensation worth at least $3,639,850 in Phathom Pharmaceuticals, Inc..

What is the salary of Azmi Nabulsi M.D., M.P.H.?

Dr. Azmi Nabulsi M.D., M.P.H. salary is $727,970 per year as Co-Founder & Chief Operating Officer in Phathom Pharmaceuticals, Inc..

How old is Azmi Nabulsi M.D., M.P.H.?

Dr. Azmi Nabulsi M.D., M.P.H. is 66 years old, born in 1959.

What stocks does Azmi Nabulsi M.D., M.P.H. currently own?

As insider, Dr. Azmi Nabulsi M.D., M.P.H. owns shares in one company:

Company Title Shares Price per share Total value
Phathom Pharmaceuticals, Inc. (PHAT) Co-Founder & Chief Operating Officer 240,421 $10.55 $2,536,442

What does Phathom Pharmaceuticals, Inc. do?

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT logo
PHAT
Phathom Pharmaceuticals, Inc.
$10.55

Azmi Nabulsi M.D., M.P.H. insider trading

Phathom Pharmaceuticals, Inc.

Dr. Azmi Nabulsi M.D., M.P.H. has made 22 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 10,901 units of PHAT stock worth $127,760 on 15 Jul 2024.

The largest trade he's ever made was exercising 20,000 units of PHAT stock on 16 May 2022. As of 15 Jul 2024 he still owns at least 240,421 units of PHAT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 10,901 $11.72 $127,760
Purchase
Common Stock 10,000 $8.26 $82,600
Purchase
Common Stock 20,000 $8.16 $163,280
Sale
Common Stock 4,457 N/A N/A
Sale
Common Stock 4,457 $37.03 $165,061
Sale
Common Stock 10,043 N/A N/A
Sale
Common Stock 10,043 $38.22 $383,813
Sale
Common Stock 9,353 $12.37 $115,706
Sale
Common Stock 9,353 $36.38 $340,271
Sale
Common Stock 5,147 $37.71 $194,088
Sale
Common Stock 9,127 $45.78 $417,807
Sale
Common Stock 9,127 $45.78 $417,807
Sale
Common Stock 9,127 $45.78 $417,807
Sale
Common Stock 5,373 $23.03 $123,724
Sale
Common Stock 5,373 $45.91 $246,685
Sale
Common Stock 9,084 $20.58 $186,958
Sale
Common Stock 5,416 N/A N/A
Sale
Common Stock 7,302 $45.31 $330,854
Sale
Common Stock 7,302 $22.79 $166,376
Sale
Common Stock 7,198 $22 $158,320
Sale
Common Stock 7,198 $44.41 $319,663
Sale
Common Stock 14,500 $36.83 $534,021
Sale
Common Stock 1,854 $33.77 $62,608
Sale
Common Stock 12,646 $11.52 $145,720

Phathom Pharmaceuticals key executives

Phathom Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: